Medical Condition

intrahepatic cholangiocarcinoma

Total Trials

8

Recruiting Now

8

Trial Phases

Phase 2, Phase 1, Phase 2, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for intrahepatic cholangiocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — intrahepatic cholangiocarcinoma Clinical Trials

How many clinical trials are currently recruiting for intrahepatic cholangiocarcinoma?

ClinicalMetric currently tracks 8 actively recruiting clinical trials for intrahepatic cholangiocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for intrahepatic cholangiocarcinoma?

intrahepatic cholangiocarcinoma research spans Phase 1 (3 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a intrahepatic cholangiocarcinoma clinical trial?

Eligibility criteria for intrahepatic cholangiocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Inova Health Care Services 1 trial

Anhui Provincial Hospital 1 trial

Beijing Biotech 1 trial

Michael J Cavnar, MD 1 trial

Azienda Sanitaria Ospedaliera 1 trial

Recruiting Clinical Trials

NCT05422690 Phase 2

Recruiting

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Inova Health Care Services

View Trial →

NCT06664021 Phase 2

Recruiting

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Anhui Provincial Hospital

View Trial →

NCT07641036 Phase 1, Phase 2

Recruiting

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)

Azienda Sanitaria Ospedaliera

View Trial →

NCT06990659

Recruiting

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

University Hospital, Angers

View Trial →

NCT06406816 EARLY_Phase 1

Recruiting

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

NCT07169734 Phase 1, Phase 2

Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Enrollment

180 pts

Location

United States, Franc...

Sponsor

Alentis Therapeutics AG

View Trial →

Related Conditions

cholangiocarcinoma (1) extrahepatic cholangiocarcinoma (1) gallbladder carcinoma (1) biliary tract cancer (1) colorectal cancer metastatic (1) hepato cellular carcinoma hcc (1) cervical squamous cell carcinoma (1) squamous non small cell lung cancer (1) colorectal cancer (1) urothelial carcinoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology